European Journal of Clinical Pharmacology

, Volume 53, Issue 6, pp 389–404

Current therapeutic uses and potential of β-adrenoceptor agonists and antagonists

  • G. Emilien
  • J.-M. Maloteaux
  • G. Emilion

DOI: 10.1007/s002280050399

Cite this article as:
Emilien, G., Maloteaux, JM. & Emilion, G. E J Clin Pharmacol (1998) 53: 389. doi:10.1007/s002280050399


β-Adrenoceptors are members of a large family of hormone and neurotransmitter receptors that initiate their biological function by coupling to GTP-binding regulatory proteins. β-Adrenoceptors can be subdivided into two main subgroups, designated β1 and β2. Atypical β-adrenoceptors or β3-adrenoceptors, which are present on adipocytes, have been demonstrated pharmacologically. Their function in adipose tissue is currently being investigated.

β2-Adrenoceptor agonists have played a key role in the treatment of asthma for some 30 years, being used for the relief and prophylaxis of symptoms. There is, however, no evidence that tolerance to the bronchodilator or anti-bronchoconstrictor effects of these drugs is responsible for the deleterious effects reported with the regular use of bronchodilators.

In neuropsychiatry, β-adrenoceptor antagonists have been used for the treatment of acute stress reactions and generalised anxiety, essential tremor and prophylaxis of migraine. In general, they are effective in anxiety disorders if the somatic symptoms are not extreme. For prophylactic treatment of migraine, β-adrenoceptor antagonists such as propranolol, metoprolol, nadolol and atenolol are the drugs of first choice.

In cardiology, β-adrenoceptor antagonists are an important class for the treatment of high blood pressure, arrhythmias and angina pectoris, and for prevention of myocardial infarction. With chronic treatment, they reduce mortality in hypertension and prolong survival in patients with coronary heart disease.

Key wordsβ-Adrenoceptor-agonistβ-Adrenoceptor-antagonist

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • G. Emilien
    • 1
  • J.-M. Maloteaux
    • 2
  • G. Emilion
    • 2
  1. 1.Wyeth Ayerst Research, European CR. and D Department, 80 Avenue du Président Wilson, Puteaux-92031, Paris La Défense, FranceFR
  2. 2.Laboratory of Pharmacology and Department of Neurology, Université Catholique de Louvain and Cliniques Universitaires Saint Luc, B-1200 Brussels, BelgiumBE